COVID-19 and Cardiovascular Disease: from Basic Mechanisms to Clinical Perspectives

Overview

Journal Nat Rev Cardiol

Specialty Cardiology & Vascular Diseases

Date 2020 Jul 22

PMID 32690910

Citations 686

Authors

Masataka Nishiga

Dao Wen Wang

Yaling Han

David B Lewis

Joseph C Wu

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic that has affected the lives of billions of individuals. Extensive studies have revealed that SARS-CoV-2 shares many biological features with SARS-CoV, the zoonotic virus that caused the 2002 outbreak of severe acute respiratory syndrome, including the system of cell entry, which is triggered by binding of the viral spike protein to angiotensin-converting enzyme 2. Clinical studies have also reported an association between COVID-19 and cardiovascular disease. Pre-existing cardiovascular disease seems to be linked with worse outcomes and increased risk of death in patients with COVID-19, whereas COVID-19 itself can also induce myocardial injury, arrhythmia, acute coronary syndrome and venous thromboembolism. Potential drug-disease interactions affecting patients with COVID-19 and comorbid cardiovascular diseases are also becoming a serious concern. In this Review, we summarize the current understanding of COVID-19 from basic mechanisms to clinical perspectives, focusing on the interaction between COVID-19 and the cardiovascular system. By combining our knowledge of the biological features of the virus with clinical findings, we can improve our understanding of the potential mechanisms underlying COVID-19, paving the way towards the development of preventative and therapeutic solutions.

Citing Articles

Prion propensity of Betacoronaviruses including SARS-CoV-2.

Haddad H, Al-Zyoud W Heliyon. 2025; 11(4):e42199.

PMID: 40034268 PMC: 11874563. DOI: 10.1016/j.heliyon.2025.e42199.

Cardiovascular outcomes in long COVID-19: a systematic review and meta-analysis.

Zhang T, Li Z, Mei Q, Walline J, Zhang Z, Liu Y Front Cardiovasc Med. 2025; 12:1450470.

PMID: 39944605 PMC: 11814196. DOI: 10.3389/fcvm.2025.1450470.

Prevalence of cardiovascular symptoms in post-acute COVID-19 syndrome: a meta-analysis.

Huang L, Li H, He B, Wang X, Zhang Q, Peng W BMC Med. 2025; 23(1):70.

PMID: 39915795 PMC: 11803987. DOI: 10.1186/s12916-025-03908-3.

Prevalence of probable post-COVID cardiac sequelae and its health seeking behaviour among health care workers: A cross-sectional analytical study.

Marimuthu Y, Nair G, Nagesh U, Anand A, Chopra K, Nagappa B Indian J Tuberc. 2025; 72(1):5-11.

PMID: 39890371 PMC: 10264162. DOI: 10.1016/j.ijtb.2023.06.008.

The Impact of Vaccinations Against Respiratory Infections on the Prognosis in Heart Failure Patients.

Jankowiak B, Wleklik M, Rosiek-Biegus M Vaccines (Basel). 2025; 12(12.

PMID: 39771983 PMC: 11679989. DOI: 10.3390/vaccines12121321.

References

Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V . Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020; 18(7):1738-1742. PMC: 9906150. DOI: 10.1111/jth.14850. View

Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F . Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020; 41(22):2070-2079. PMC: 7239100. DOI: 10.1093/eurheartj/ehaa408. View

Dai W, Zhang B, Jiang X, Su H, Li J, Zhao Y . Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020; 368(6497):1331-1335. PMC: 7179937. DOI: 10.1126/science.abb4489. View

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Inciardi R, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D . Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7):819-824. PMC: 7364333. DOI: 10.1001/jamacardio.2020.1096. View

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

Lakkireddy D, Chung M, Gopinathannair R, Patton K, Gluckman T, Turagam M . Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the.... Circulation. 2020; 141(21):e823-e831. PMC: 7243667. DOI: 10.1161/CIRCULATIONAHA.120.047063. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

10.

Andersen P, Ianevski A, Lysvand H, Vitkauskiene A, Oksenych V, Bjoras M . Discovery and development of safe-in-man broad-spectrum antiviral agents. Int J Infect Dis. 2020; 93:268-276. PMC: 7128205. DOI: 10.1016/j.ijid.2020.02.018. View

11.

Burrell L, Risvanis J, Kubota E, Dean R, Macdonald P, Lu S . Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005; 26(4):369-75. DOI: 10.1093/eurheartj/ehi114. View

12.

Puelles V, Lutgehetmann M, Lindenmeyer M, Sperhake J, Wong M, Allweiss L . Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020; 383(6):590-592. PMC: 7240771. DOI: 10.1056/NEJMc2011400. View

13.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

14.

de Abajo F, Rodriguez-Martin S, Lerma V, Mejia-Abril G, Aguilar M, Garcia-Luque A . Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020; 395(10238):1705-1714. PMC: 7255214. DOI: 10.1016/S0140-6736(20)31030-8. View

15.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

16.

Suthar M, Zimmerman M, Kauffman R, Mantus G, Linderman S, Hudson W . Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Rep Med. 2020; 1(3):100040. PMC: 7276302. DOI: 10.1016/j.xcrm.2020.100040. View

17.

Chen L, Li X, Chen M, Feng Y, Xiong C . The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020; 116(6):1097-1100. PMC: 7184507. DOI: 10.1093/cvr/cvaa078. View

18.

Reynolds H, Adhikari S, Pulgarin C, Troxel A, Iturrate E, Johnson S . Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020; 382(25):2441-2448. PMC: 7206932. DOI: 10.1056/NEJMoa2008975. View

19.

Manka R, Karolyi M, Polacin M, Holy E, Nemeth J, Steiger P . Myocardial edema in COVID-19 on cardiac MRI. J Heart Lung Transplant. 2020; 39(7):730-732. PMC: 7834291. DOI: 10.1016/j.healun.2020.04.025. View

20.

De Filippo O, DAscenzo F, Angelini F, Bocchino P, Conrotto F, Saglietto A . Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy. N Engl J Med. 2020; 383(1):88-89. PMC: 7224608. DOI: 10.1056/NEJMc2009166. View